Browsing Tag
AIM London
3 posts
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
Intellect Design Arena (NSE: INTELLECT), Fintel (AIM: FNTL) launch JV targeting wealth management leadership
Intellect Design Arena and Fintel PLC launch a 50:50 UK AI joint venture to rebuild advisory technology infrastructure. Read what this means for both stocks.
Victoria PLC (LSE: VCP) warned of weak footfall. The real question is whether its refinancing can hold
Victoria PLC (VCP.L) cuts FY2026 EBITDA guidance to £95m from £110.7m. What's behind the miss and what it means for 2027. Read the full analysis.